Physician profile
Stacy Stuart
NPI 1073120960
$3,813.40
in general payments reported to CMS, 2019-2025
18 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,505 · 2022: $1,097 · 2023: $812 · 2024: $14.50 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $692.31 | 2021-2023 | Lybalvi, Aristada |
| Abbvie INC. | $651.91 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $548.84 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $545.60 | 2021-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $374.77 | 2021-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $179.92 | 2022-2023 | Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.20 | 2021-2022 | |
| Lundbeck LLC | $161.20 | 2021-2023 | Abilify Maintena, Rexulti |
| Neuronetics, INC. | $118.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.66 | 2021 | |
| Neos Therapeutics, Lp | $63.47 | 2021-2022 | |
| Tris Pharma INC | $49.89 | 2021-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $40.74 | 2022 | |
| Vanda Pharmaceuticals INC. | $39.73 | 2021-2022 | |
| Axsome Therapeutics, INC. | $27.29 | 2022-2023 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $27.16 | 2023 | Sertraline Hcl, Loreev Xr |
| Corium, LLC | $26.19 | 2021 | |
| Adlon Therapeutics L.P. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.